The Native Antigen Company is part of LGC Clinical Diagnostics - Learn More

0 Items
Select Page

Human IgA Anti-SARS-CoV-2 Spike Antibody (A60H)

$364.25$714.55 excl. VAT

Anti-SARS-CoV-2 Spike antibody (A60H) is a recombinant monoclonal antibody that recognizes the SARS-CoV and SARS-CoV-2 Spike glycoprotein, the causative agent of COVID-19. Antibody binds to both SARS-CoV and SARS-CoV-2 with high affinity at the Receptor Binding Domain (RBD) in the S1 subunit of the Spike protein.

MAB12439_ELISA

ELISA: Binding of Anti-SARS-CoV-2 Spike protein, IgA to immobilized SARS-CoV-2 Spike protein RBD determined by ELISA.

HUMAN IGA ANTI-SARS-COV-2 SPIKE ANTIBODY (A60H)

Human IgA Anti-SARS-CoV-2 Spike antibody (A60H) is a recombinant monoclonal antibody that recognizes the SARS-CoV and SARS-CoV-2 Spike glycoprotein, the causative agent of COVID-19. Antibody binds to both SARS-CoV and SARS-CoV-2 with high affinity at the Receptor Binding Domain (RBD) in the S1 subunit of the Spike protein.

 

PRODUCT DETAILS – HUMAN IGA ANTI-SARS-COV-2 SPIKE ANTIBODY (A60H)

  • Recombinant anti SARS-CoV-2 Spike IgA antibody
  • Isotype – Human IgA
  • Binds the SARS-CoV Spike protein as well as SARS-CoV-2 (COVID-19) Spike protein
  • Presented in PBS
  • Suitable for use in ELISA

 

BACKGROUND

Human coronaviruses are the major cause of upper respiratory tract illness. They are positive-stranded RNA viruses, and contain the largest viral RNA genomes known to date (27-31 kb). SARS (severe acute respiratory syndrome) and COVID-19 are both caused by human coronaviruses, SARS-CoV and SARS-CoV-2, respectively. The genome of SARS-CoV-2 shares 82% nucleotide identity with human SARS-CoV and 89% with bat SARS-like-CoVZXC21 (Lu et al., 2020; Zhao et al., 2020). However, it displays lower pathogenicity and higher human to human transmissibility (Li et al., 2020). The coronavirus genome encodes four structural proteins: the spike (S) protein, nucleocapsid (N) protein, membrane (M) protein, and the envelope (E) protein. Cell entry is the first step in cross-species transmission and SARS-CoV-2 is likely to infect lung type II alveolar cells, which may explain the severe alveolar damage observed after infection (Zhao et al., 2020). Both SARS-CoV and SARS-CoV-2 uses the spike (S) protein to gain entry into host cells and it has been shown that the spike RBD binds the entry receptor angiotensin-converting enzyme 2 (ACE2) on infected cells. It is predicted that SARS-CoV-2 recognizes human ACE2 more efficiently than SARS -CoV (Wan et al., 2020). Therefore, the S protein is considered a key target for vaccine development (Li et al, 2020).

 

REFERENCES

Product datasheet
Safety datasheet

Ice Packs